Table Filtering
Other Information
Release Statistics Download
GlyCosmos Glycolipids

Glycolipid entries from the LIPID MAPS Structure Database (LMSD).

Source Last Updated
LIPID MAPS Proteome Database (LMSD) June 16, 2024
Displaying entries 1976 - 2000 of 6046 in total
Sub Class LM ID Name LipidBank ID KEGG ID PubChem CID ChEBI ID Exact Mass ▲ Formula
Diacylglycerophosphoinositolglycans LMGP15010237
  • 2'-O-(alpha-D-Manp)-6'-O-(alpha-D-Manp-1->6-alpha-D-Manp-1->6-alpha-D-Manp-1->6-alpha-D-Manp)-(1-(9Z,12Z-nonadecadienoyl)-2-hexadecanoyl-sn-glycero-3-phospho-1'-myo-inositol)
  • PIM5(19:2(9Z,12Z)/16:0)
126457605 1658.805608 C74H131O38P
Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc- (Lacto series) LMSP0504AI06
  • Fucalpha1-2Galbeta1-3(Fucalpha1-4)GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/26:0)
  • Leb(d18:1/26:0)
44260681 1659.022263 C82H150N2O31
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505AG06
  • Fucalpha1-2Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/26:0)
  • Ley-6(d18:1/26:0)
44261025 1659.022263 C82H150N2O31
Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502BH04
  • Fucalpha2-3GlcNAcbeta1-6GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/22:0)
44260431 1659.981127 C80H145N3O32
GalNAcbeta1-4Galbeta1-4Glc- (Ganglio series) LMSP0503AG04
  • Fucalpha1-3GlcNAcbeta1-3Galbeta1-3GalNAcbeta1-4Galbeta1-4Glcbeta-Cer(d18:1/22:0)
44260535 1659.981127 C80H145N3O32
Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc- (Lacto series) LMSP0504AF04
  • GalNAcalpha1-3(Fucalpha1-2)Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/22:0)
  • type I A antigen(d18:1/22:0)
44260655 1659.981127 C80H145N3O32
Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc- (Lacto series) LMSP0504AK04
  • Fucalpha1-4GlcNAcbeta1-3Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/22:0)
44260695 1659.981127 C80H145N3O32
Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc- (Lacto series) LMSP0504AR04
  • GlcNAcbeta1-3Galbeta1-3(Fucalpha1-4)GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/22:0)
44260751 1659.981127 C80H145N3O32
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505AF04
  • GalNAcbeta1-3(Fucalpha1-2)Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/22:0)
  • type II A antigen(d18:1/22:0)
44261015 1659.981127 C80H145N3O32
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505CG04
  • ClcNAc-Lex-5(d18:1/22:0)
  • GlcNAcbeta1-3Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/22:0)
44261439 1659.981127 C80H145N3O32
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505CU04
  • GalNAcalpha1-3(Fucalpha1-2)Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/22:0)
  • type II A antigen(d18:1/22:0)
44261543 1659.981127 C80H145N3O32
Galalpha1-3Galbeta1-4Glc- (Isoglobo series) LMSP0506BI04
  • Fucalpha1-3GlcNAcbeta1-3Galalpha1-3(GalNAcbeta1-4)Galbeta1-4Glcbeta-Cer(d18:1/22:0)
44261695 1659.981127 C80H145N3O32
Diacylglycerophosphoinositolglycans LMGP15010205
  • 2'-O-(alpha-D-Manp)-6'-O-(alpha-D-Manp-1->6-alpha-D-Manp-1->6-alpha-D-Manp-1->6-alpha-D-Manp)-(1-heptadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phospho-1'-myo-inositol)
  • PIM5(17:0/18:1(9Z))
126457573 1660.821258 C74H133O38P
Diacylglycerophosphoinositolglycans LMGP15010226
  • 2'-O-(alpha-D-Manp)-6'-O-(alpha-D-Manp-1->6-alpha-D-Manp-1->6-alpha-D-Manp-1->6-alpha-D-Manp)-(1-nonadecanoyl-2-(9Z-hexadecenoyl)-sn-glycero-3-phospho-1'-myo-inositol)
  • PIM5(19:0/16:1(9Z))
126457594 1660.821258 C74H133O38P
Diacylglycerophosphoinositolglycans LMGP15010231
  • 2'-O-(alpha-D-Manp)-6'-O-(alpha-D-Manp-1->6-alpha-D-Manp-1->6-alpha-D-Manp-1->6-alpha-D-Manp)-(1-(9Z-nonadecenoyl)-2-hexadecanoyl-sn-glycero-3-phospho-1'-myo-inositol)
  • PIM5(19:1(9Z)/16:0)
126457599 1660.821258 C74H133O38P
Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502BB02
  • GalNAcalpha1-3GalNAcbeta1-3(GalNAcbeta1-4)Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/18:0)
44260381 1660.939991 C78H140N4O33
Galalpha1-3Galbeta1-4Glc- (Isoglobo series) LMSP0506AL02
  • GalNAcalpha1-3GalNAcbeta1-3Galalpha1-3(GlcNAcbeta1-6)Galbeta1-4Glcbeta-Cer(d18:1/18:0)
44261901 1660.939991 C78H140N4O33
Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AQ07
  • GalNAcbeta1-3Galalpha1-3Galalpha1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))
44260298 1660.965143 C80H144N2O33
Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502BF07
  • Galalpha1-3Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))
44260418 1660.965143 C80H144N2O33
Galalpha1-3Galbeta1-4Glc- (Isoglobo series) LMSP0506BA07
  • Galalpha1-3Galbeta1-3GalNAcbeta1-3Galalpha1-3Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))
44261634 1660.965143 C80H144N2O33
Diacylglycerophosphoinositolglycans LMGP15010204
  • 2'-O-(alpha-D-Manp)-6'-O-(alpha-D-Manp-1->6-alpha-D-Manp-1->6-alpha-D-Manp-1->6-alpha-D-Manp)-(1-heptadecanoyl-2-octadecanoyl-sn-glycero-3-phospho-1'-myo-inositol)
  • PIM5(17:0/18:0)
126457572 1662.836908 C74H135O38P
Diacylglycerophosphoinositolglycans LMGP15010225
  • 2'-O-(alpha-D-Manp)-6'-O-(alpha-D-Manp-1->6-alpha-D-Manp-1->6-alpha-D-Manp-1->6-alpha-D-Manp)-(1-nonadecanoyl-2-hexadecanoyl-sn-glycero-3-phospho-1'-myo-inositol)
  • PIM5(19:0/16:0)
126457593 1662.836908 C74H135O38P
Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AQ05
  • GalNAcbeta1-3Galalpha1-3Galalpha1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:0)
44260296 1662.980793 C80H146N2O33
Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502BF05
  • Galalpha1-3Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:0)
44260416 1662.980793 C80H146N2O33
Galalpha1-3Galbeta1-4Glc- (Isoglobo series) LMSP0506BA05
  • Galalpha1-3Galbeta1-3GalNAcbeta1-3Galalpha1-3Galbeta1-4Glcbeta-Cer(d18:1/24:0)
44261632 1662.980793 C80H146N2O33

About Release Notes Help Feedback

Click here to visit the beta site.


International Collaboration

GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.

Acknowledgements

Supported by JST NBDC Grant Number JPMJND2204

Partly supported by NIH Common Fund Grant #1U01GM125267-01


Logo License Policies Site Map

Contact: support@glycosmos.org

This work is licensed under Creative Commons Attribution 4.0 International


GlyCosmos Portal v4.0.0

Last updated: August 19, 2024